Clinical Trials
72 trialsNCT03910660 2026-05-15
A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.
BioXcel Therapeutics Inc
Phase 1/2 Completed
NCT04727723 2026-05-04
REAL-LU
Novartis
Completed
NCT05361668 2026-03-19
Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome
Crinetics Pharmaceuticals Inc.
Phase 2 Completed
NCT05844332 2025-12-22
LUTATHERA Injection General Use Result Survey
Novartis
Completed
NCT06358001 2025-09-22
EchoTip AcuCore Post-Market Clinical Study
Cook Group Incorporated
Completed
NCT05077384 2025-09-16
Open-label Study of Surufatinib in Japanese Patients
Hutchmed
Phase 1/2 Completed
NCT05017662 2025-09-04
A Long-term Safety Surveillance Study in Participants Previously Treated With 177Lu-IPN01072
Ariceum Therapeutics GmbH
Phase NA Completed
NCT02611024 2025-07-09
Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
PharmaMar
Phase 1/2 Completed
NCT02279433 2025-06-24
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
Nuvation Bio Inc.
Phase 1 Completed
NCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT04438304 2025-02-12
A Diagnostic Imaging Study of 64Cu-SARTATE Using PET on Patients With Known or Suspected Neuroendocrine Tumors (DISCO)
Clarity Pharmaceuticals Ltd
Phase 2 Completed
NCT02842749 2025-02-10
Phase IV Study of the Safety and Efficacy of Everolimus in Adult Patients With Progressive pNET in China
Novartis
Phase 4 Completed
NCT04524442 2025-01-24
Post-Authorization Safety Study (PASS) of LysaKare® in Adult Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET) Patients
Advanced Accelerator Applications
Phase 4 Completed
NCT06253897 2024-12-24
BackSOM
Ipsen
Completed
NCT04028479 2024-12-18
ROOT
Taproot Health
Completed
NCT04649580 2024-12-17
PREF-NET
Ipsen
Completed
NCT01794793 2024-10-01
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
RECORDATI GROUP
Phase 4 Completed
NCT04852679 2024-10-01
PALACE
Ipsen
Phase 3 Completed
NCT03223428 2024-07-24
RELAX
TerSera Therapeutics LLC
Completed
NCT02282059 2024-06-20
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Pfizer
Completed
NCT05816720 2023-04-18
Retrospective Analysis of Patients Re-treated With Lutetium-177 DOTATATE (Lutathera®)
Novartis
Completed
NCT02588170 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT02589821 2023-03-30
Phase III Study of Surufatinib in Treating Advanced Pancreatic Neuroendocrine Tumors
Hutchmed
Phase 3 Completed
NCT03673943 2022-12-22
Imaging of Patients With Known or Suspected Somatostatin Receptor Positive Neuroendocrine Tumors Using Cu64-DOTATATE
Radiomedix, Inc.
Phase 3 Completed
NCT00774930 2022-10-14
ELECT
Ipsen
Phase 3 Completed
NCT00842348 2022-10-12
NET729
Ipsen
Phase 3 Completed
NCT03411915 2022-05-10
DUET-1
Xencor, Inc.
Phase 1 Completed
NCT01578239 2022-04-04
NETTER-1
Advanced Accelerator Applications
Phase 3 Completed
NCT02936323 2021-12-14
PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers
Tarveda Therapeutics
Phase 1/2 Completed
NCT02630654 2021-12-07
EXPLAIN
Ipsen
Completed
NCT01524783 2021-08-05
RADIANT-4
Novartis
Phase 3 Completed
NCT01789281 2021-06-11
Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.
Novartis
Phase 4 Completed
NCT03220217 2021-01-14
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
Ipsen
Phase 2 Completed
NCT01364415 2020-12-21
Dose Escalation Study of Pasireotide (SOM230) in Patients With Advanced Neuroendocrine Tumors (NETs)
Novartis
Phase 1 Completed
NCT00326469 2020-11-05
Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
Ipsen
Phase 2 Completed
NCT01234168 2020-11-05
SYMNET
Ipsen
Completed
NCT02698410 2020-10-01
ATLANT
Ipsen
Phase 2 Completed
NCT02355535 2020-09-24
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 1
Vanquish Oncology, Inc.
Phase 1 Completed
NCT03562091 2020-08-28
OPERA
Ipsen
Completed
NCT02730104 2020-06-26
Community-based Neuroendocrine Tumor (NET) Research Study
Ipsen
Completed
NCT04440956 2020-06-22
An Imaging Study of 64Cu-SARTATE Using Positron Emission Tomography in Patients With Neuroendocrine Tumours
Clarity Pharmaceuticals Ltd
Phase EARLY_PHASE1 Completed
NCT03112694 2020-06-02
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
Ipsen
Completed
NCT01970540 2020-03-09
Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors
PharmaMar
Phase 1 Completed
NCT02162446 2019-10-02
68Ga-OPS202 Study for Diagnostic Imaging of GEP NET
Ipsen
Phase 1/2 Completed
NCT00781911 2019-09-20
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
Phase 2 Completed
NCT01525550 2019-07-30
A Study Of The Efficacy And Safety Of Sunitinib In Patients With Advanced Well-Differentiated Pancreatic Neuroendocrine Tumors
Pfizer
Phase 4 Completed
NCT02075606 2019-06-07
CALM-NET
Ipsen
Phase 4 Completed
NCT02231762 2019-05-06
SONNET
Ipsen
Phase 2 Completed
NCT01590199 2019-04-16
MACS2002
Novartis
Phase 1 Completed